Amphastar Pharmaceuticals, Inc. (AMPH): R&D Expense
$85.84M
Year ended 2025-12-31
$94.57M
Trailing 12 months to 2026-06-30
+4.7%
3-year compound annual growth
+5.0%
5-year compound annual growth
+8.7%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $85.84M | +16.1% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $73.91M | +0.2% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $73.74M | -1.4% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $74.77M | +22.7% | 2025-03-03, From 2022-01-01 |
| 2021-12-31 | $60.93M | -9.4% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $67.23M | -2.4% | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | $68.85M | +19.6% | 2022-03-11, From 2019-01-01 |
| 2018-12-31 | $57.56M | +32.3% | 2021-03-15, From 2018-01-01 |
| 2017-12-31 | $43.50M | +4.8% | 2020-03-16, From 2017-01-01 |
| 2016-12-31 | $41.52M | +11.4% | 2019-03-15, From 2016-01-01 |
| 2015-12-31 | $37.27M | +29.1% | 2018-03-14, From 2015-01-01 |
| 2014-12-31 | $28.87M | n/c | 2017-03-15, From 2014-01-01 |
| 2013-12-31 | $33.02M | +6.0% | 2016-03-15, From 2013-01-01 |
| 2012-12-31 | $31.16M | n/a | 2015-03-26, From 2012-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $85.84M | +16.1% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $106.23M | -2.4% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $117.31M | +43.8% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $53.20M | -24.8% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $254.91M | +3.2% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $96.85M | -13.2% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | $750.00M | +7.4% |
| Collegium Pharmaceutical, Inc (COLL) | 2024-12-31 | $0 | n/a |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $183.28M | -2.0% |
Compare AMPH, SUPN, PCRX, EBS side by side · Screen every company in Pharmaceutical Preparations ↗